Accueil > Actualité
Actualite financiere : Actualite bourse

GSK: vaccine continues to drive growth in Q2

( - On Wednesday GSK reported higher EPS and sales for Q2, as it continued to benefit from strong demand for its shingles vaccine, Shingrix.

This morning the UK's leading pharmaceutical company announced Q2 adjusted EPS of 34.7p, up 6% LFL.

Meanwhile, revenue rose 13% to 6.9 billion pounds (on a currency-adjusted basis), driven by double-digit growth at Shingrix, which set new sales records.

Following what it described as a "strong" performance, the group, which recently spun off its Haleon consumer medicines business, raised its annual guidance, now expecting adjusted EPS to increase by around 1% in 2022, based on expected sales growth of 6% to 8%.

However, UBS analysts said that the increase was limited in scope: the stock is currently up only about 0.5% in London after these announcements.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.